Vyxeos® Liposomal – indicated populations

Vyxeos® Liposomal: Who?

Vyxeos Liposomal is indicated for the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)1

video_preview_play_button

*t-AML: ~7% OF AML CASES3, AML-MRC: ~25% OF AML CASES6

**In the absence of mutations of NPM1 or biallelic mutation of CEBPA4

†Comparator arm conventional chemotherapy is 7+3 in induction, 5+2 in second induction and consolidation where given

‡High-risk AML is defined as therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm

References

  1. Vyxeos Liposomal – Summary of Product Characteristics, October 2019
  2. Boddu PC et al. Cancer 2017; 123(16): 3050-3060
  3. Granfeldt Østgård LS et al. J Clin Oncol 2015; 33(31): 3641-3649
  4. Arber DA et al. Blood 2016; 127(20): 2391-2405
  5. Lancet JE et al. J Clin Oncol 2018; 36(26): 2684-2692
  6. Nagel G et al. Ann Hematol 2017; 96(12): 1993-2003
  7. National Cancer Institute. Cancer Terms. Available from: www.cancer.gov/publications/dictionaries/cancer-terms/def/t-aml. Accessed May 2020.
  8. Weinburg OK et al. Blood 2009; 113(9): 1906-1908
  9. Drummond MW. Int J Hematol 2019; 8(2): IJH16
  10. Fernandez HF et al. Hematology Am Soc Hematol Educ Program 2010; 2010: 56–61
  11. Mayer LD et al. Int J Nanomedicine 2019; 14: 3819–3830

 

ADVERSE EVENTS REPORTING

 

Reporting of side effects: Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse reactions via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email: AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765

 

INT-VYX-2000063 | June 2020